A biotech emerges from one Deer­field­'s R&D do­na­tion part­ners

Two years ago, Deer­field be­gan writ­ing large checks to pres­ti­gious re­search in­sti­tutes as part of a strat­e­gy to get in on the ground floor of top trans­la­tion­al work. The close re­la­tion­ship they built with one of those in­sti­tutes – Dana Far­ber – has now led to a new biotech.

Civet­ta Ther­a­peu­tics an­nounced $53 mil­lion in Se­ries A fund­ing to ap­ply pro­tein-pro­tein in­ter­ac­tion tech­nol­o­gy from the Dana Far­ber Can­cer In­sti­tute and the Broad In­sti­tute to can­cer and neu­rode­gen­er­a­tive dis­eases, among oth­er tar­gets. The sci­en­tif­ic founders were Er­ic Fis­ch­er, head of the new Deer­field-en­dowed Cen­ter for Pro­tein Degra­da­tion at Dana Far­ber, and William Sell­ers, who led on­col­o­gy re­search at No­var­tis for 11 years be­fore re­turn­ing to Har­vard and Dana-Far­ber. No in­vestor be­sides Deer­field was named.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.